Madrigal Pharmaceuticals Announces New Analyses From Phase 3 MAESTRO-NASH Trial Of Resmetirom To Be Presented At EASL Congress, June 5-8, 2024 In Milan, Italy
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals announced new analyses from its Phase 3 MAESTRO-NASH trial of Resmetirom, to be presented at the EASL Congress in June 2024. The analyses show significant improvements in fibrotic features, liver stiffness, and health-related quality of life for patients treated with Resmetirom.
June 06, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Madrigal Pharmaceuticals' new analyses from the Phase 3 MAESTRO-NASH trial show Resmetirom significantly improves key fibrotic features, liver stiffness, and health-related quality of life. These findings will be presented at the EASL Congress in June 2024.
The positive results from the Phase 3 MAESTRO-NASH trial, including improvements in fibrosis, liver stiffness, and quality of life, are likely to boost investor confidence in Madrigal Pharmaceuticals. The upcoming presentation at a major congress further highlights the significance of these findings.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100